Interview With Rick G. CEO Abbvie Inc.

https://m.youtube.com/watch?v=p4rtZXXliik

Rest assured Abbvie is in good hands.

 

Partial summary of interview ,,,,,,Post Additional Commemts Below

C Suite is viewing this Thread.....Let them know what you think of Gonzalez

PLEASE,,,,,, NO LAME DUCK DIPLOMA COMMENTS That's shit is "gettin" OLD AND WEAK


Humira is safe until 2022 with additional indications

No layoffs

Pipeline strong

Ricky as a Cancer survivor, views Pharma from a different perspective

Pharmacylics acquisition blind bid was only 4% higher than competition bid

20 new drugs by 2020

 

DITTO

 

-ya man

 

RG + ChIraq's crime rate = invest in a mortuary.

 

Why the need to lie-he can't tell the truth?

 

Rick got 100k bet on the Giants !

 

Richard lost 2 days pay ? WTF

 

Levity has its place, but please not here. These are serious times and the holidays are over. So stop this silly banter - you sound like a bunch of idiot fartbags. You are the HEART of the Company critical to our success. Starting today aim for excellence and you will be richly rewarded.

 

Grasshopper is that you my son ?

 

My farts don't stink--- only yours do

 

AbbVie chief Richard Gonzalez joins the 10% price-hike pledge, but other CEOs aren't buying it
by Tracy Staton |
Jan 12, 2017 9:53am

Speaking at the J.P. Morgan Healthcare Conference, AbbVie CEO Richard Gonzalez said his company would limit 2017 price hikes to single digits.
ShareFacebookTwitterLinkedInEmailPrint
AbbVie joined the 10% price-hike pledge on Wednesday, following Allergan and Novo Nordisk, as the drug pricing debate sent biopharma shares reeling once again.

CEO Richard Gonzalez announced at the J.P. Morgan Healthcare Conference that his company, which makes the behemoth anti-inflammatory disease therapy Humira, would raise prices on its products only once in 2017, and then only by single-digit percentages.

The conference has been full of pricing talk, with some pharma execs specifically eschewing price-increase limits—and others outright mocking drugmakers’ moves to keep price hikes under 10%. As some noted, 10% still beats inflation by quite a margin.

“Promising to raise prices no more than 10% and then raising them 9.9% is not the answer,” Regeneron CEO Len Schleifer during his JPM presentation, adding that Regeneron does not raise the prices on its drugs. “A CEO gets up here and says, 'We price to value.' If that's true, why raise the price later that year, the next year? … The value hasn't changed.”

Meanwhile on Wednesday, President-elect Donald Trump shocked the drug industry at his first press conference since July, saying that pharma is “getting away with murder.” Trump promised to not only roll out competitive bidding for drugs but also pressure companies to manufacture their meds in the U.S.

Trump’s move bore out a warning from Allergan CEO Brent Saunders late last year, as many in the industry assumed that the newly elected president would be kinder to pharma than his opponent Hillary Clinton, who’d laid out several proposals for controlling drug prices. Saunders had been the first pharma chief to promise to limit price increases to 10% (and since has rolled out a slate of 9.9% hikes).

“Limit your price increases before we all face the impact of government regulation that stifles innovation and patient care,” Saunders warned in a Forbes op-ed.

Since then, Novo Nordisk’s North America chief, Jakob Riis, wrote a pricing manifesto of his own, pledging to limit price increases on insulin and further help patients who can’t afford their out-of-pocket costs. Like some other pharma executives, Riis also called out the drug supply chain—which routes drug-buying through pharmacy benefits managers, other payers, wholesalers and pharmacies—as a culprit in boosting prices, saying Novo would work with other industry leaders to reform the U.S. pricing system.

But many other drugmakers aren’t following suit. Also at J.P. Morgan on Wednesday, Mylan CEO Heather Bresch said her company isn’t interested in that approach; like Schleifer, she said a 10% limit is not the right answer.

 

Let us all engage ourselves in a moment or two of CELEBRATION !! We are blessed with great Leadership.
Wall Street will reward us handsomely and you can take that to the bank !

 

Humira is making big bucks It will continue into 2022 Ricky Trumped Trump Stock holding above $60 I would raise Humira price as much as I could Milk this blockbuster till the end Raise it 20% and the hell with politicians

 

- proves that lying ricky has no industry respect

 

Rick holds the biggest pharma blockbuster in the world, HUMIRA ! He knows pharma like the back of his hand and will keep it safe WELL INTO 2022. Its hilarious watching the little mice squeak on here EEK EEK

 

They dont call Gonzalez the "Brain" for nothing. Didnt he have a 4.0 GPA in college ?

 

Nickname was 'Speedy'. Yes he graduated sum cum laude and completed his degree in only 3 years, at age 19 1/2. A genius. We are lucky to have him as our CEO.

 

I thought it was 3.9 Well low and behold our leader is a smart one and handsome too

 

you guys are the definition of STUPID......

remember Ricky got caught by the Chicago media for lying about his virtual degrees